RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
1-Year Return
25.98%
This Quarter Return
+22.15%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$2.76B
AUM Growth
+$164M
(+6.3%)
Cap. Flow
-$52M
Cap. Flow
% of AUM
-1.88%
Top 10 Holdings %
Top 10 Hldgs %
29.44%
Holding
155
New
8
Increased
52
Reduced
20
Closed
10
Top Buys
| 1 |
Boston Scientific
BSX
|
$24.2M |
| 2 |
ALLK
Allakos
ALLK
|
$18.2M |
| 3 |
Encompass Health
EHC
|
$17.7M |
| 4 |
Elanco Animal Health
ELAN
|
$13.1M |
| 5 |
Zimmer Biomet
ZBH
|
$8.41M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$26.8M |
| 2 |
AbbVie
ABBV
|
$26M |
| 3 |
Gilead Sciences
GILD
|
$25.9M |
| 4 |
Acadia Healthcare
ACHC
|
$19.5M |
| 5 |
NUVA
NuVasive, Inc.
NUVA
|
$19.4M |
Sector Composition
| 1 | Healthcare | 89.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Assembly Biosciences
ASMB
$183M
| $18.2M | 0.66% |
40,833
+3,333
| +9% | +$1.49M |
|
52
Insmed
INSM
$30.7B
| $18M | 0.65% |
890,000
+65,000
| +8% | +$1.31M |
|
53
Theravance Biopharma
TBPH
$703M
| $18M | 0.65% |
550,000
-102,600
| -16% | -$3.35M |
|
54
Biogen
BIIB
$20.6B
| $17.7M | 0.64% |
50,000
-3,000
| -6% | -$1.06M |
|
|
ARNA
55
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $17.3M | 0.62% |
375,000
| – | – |
|
56
Ascendis Pharma
ASND
$12.5B
| $17.3M | 0.62% |
243,500
| – | – |
|
57
Alnylam Pharmaceuticals
ALNY
$59.2B
| $17.2M | 0.62% |
196,500
+23,000
| +13% | +$2.01M |
|
|
BOLD
58
DELISTED
Audentes Therapeutics, Inc
BOLD
| $16.8M | 0.61% |
425,025
-14,975
| -3% | -$593K |
|
59
Heron Therapeutics
HRTX
$201M
| $16.6M | 0.6% |
525,000
| – | – |
|
60
AnaptysBio
ANAB
$613M
| $16.5M | 0.6% |
165,000
+15,000
| +10% | +$1.5M |
|
|
IMMU
61
DELISTED
Immunomedics Inc
IMMU
| $16.1M | 0.58% |
775,000
+275,000
| +55% | +$5.73M |
|
|
BPMC
62
DELISTED
Blueprint Medicines
BPMC
| $15.6M | 0.57% |
200,000
+1,000
| +0.5% | +$78.1K |
|
63
Ultragenyx Pharmaceutical
RARE
$3.07B
| $15.3M | 0.55% |
200,000
| – | – |
|
|
ECYT
64
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $15.1M | 0.55% |
850,000
+175,000
| +26% | +$3.11M |
|
|
RARX
65
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $13.6M | 0.49% |
750,000
| – | – |
|
66
Rigel Pharmaceuticals
RIGL
$742M
| $13.2M | 0.48% |
412,500
+17,500
| +4% | +$562K |
|
|
XENT
67
DELISTED
Intersect ENT, Inc
XENT
| $13.2M | 0.48% |
460,000
+50,000
| +12% | +$1.44M |
|
|
EPZM
68
DELISTED
Epizyme, Inc
EPZM
| $13.2M | 0.48% |
1,241,253
| – | – |
|
|
69
Elanco Animal Health
ELAN
$9.16B
| $13.1M | 0.47% |
+375,000
| New | +$13.1M |
|
70
Aclaris Therapeutics
ACRS
$227M
| $12.8M | 0.46% |
880,000
+24,000
| +3% | +$348K |
|
71
argenx
ARGX
$45.9B
| $12.5M | 0.45% |
165,000
+36,250
| +28% | +$2.75M |
|
|
MNTA
72
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $12.5M | 0.45% |
475,000
+22,500
| +5% | +$592K |
|
|
GTHX
73
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $12.2M | 0.44% |
233,073
-66,927
| -22% | -$3.5M |
|
74
BioMarin Pharmaceuticals
BMRN
$11.1B
| $12.1M | 0.44% |
125,000
| – | – |
|
75
Amicus Therapeutics
FOLD
$2.46B
| $12.1M | 0.44% |
1,000,000
| – | – |
|